Cochrane · systematic review · CD014945
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
Hirsch, C, Park, YS, Piechotta, V, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
38
current version
GRADE rated
23
No studies
15
Included studies
NR
No studies 15 · 39.5%Ungraded 0 · 0%Very low 3 · 7.9%Low 14 · 36.8%Moderate 2 · 5.3%High 4 · 10.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tixagevimab/cilgavimab compared to placebo for pre‐exposure prophylaxis of COVID‐19
Population: SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infection with SARS‐CoV‐2 within 6 months Tixagevimab/cilgavimab vs placebo | RR 0.45 [0.29, 0.7] | 1 study · 4685 participants | Moderate Downgraded: risk of bias |
Development of clinical COVID‐19 symptoms within 6 months Tixagevimab/cilgavimab vs placebo | RR 0.18 [0.09, 0.35] | 1 study · 5172 participants | High |
All‐cause mortality within 6 monthsb Tixagevimab/cilgavimab vs placebo | RR 0.64 [0.24, 1.73] | 1 study · 5197 participants | Low Downgraded: risk of bias, imprecision |
Admission to hospital within 6 monthsb Tixagevimab/cilgavimab vs placebo | RR 0.03 [0, 0.59] | 1 study · 5197 participants | Low Downgraded: imprecision |
Quality of life at longest Tixagevimab/cilgavimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 1 to 2 Tixagevimab/cilgavimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 3 to 4 within 6 months Tixagevimab/cilgavimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: all grade within 6 monthsb Tixagevimab/cilgavimab vs placebo | RR 1 [0.94, 1.07] | 1 study · 5197 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events within 6 monthsb Tixagevimab/cilgavimab vs placebo | RR 1.12 [0.83, 1.52] | 1 study · 5197 participants | Low Downgraded: risk of bias, imprecision |
Casirivimab/imdevimab compared to placebo for pre‐exposure prophylaxis of COVID‐19
Population: SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Infection with SARS‐CoV‐2 within 6 monthsa Casirivimab/imdevimab vs placebo | RR 0.01 [0, 0.14] | 1 study · 825 participants | Low Downgraded: risk of bias, imprecision |
Development of clinical COVID‐19 symptoms within 6 months Casirivimab/imdevimab vs placebo | RR 0.02 [0, 0.27] | 1 study · 969 participants | Low Downgraded: risk of bias, imprecision |
All‐cause mortality within 6 months Casirivimab/imdevimab vs placebo | no estimate extracted | 1 study · 969 participants | Very low Downgraded: risk of bias, imprecision |
Admission to hospital within 6 months Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Quality of life at longest Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 1 to 2 Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 3 to 4 within 6 months Casirivimab/imdevimab vs placebo | RR 0.44 [0.1, 1.95] | 1 study · 969 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events: all grades within 6 months Casirivimab/imdevimab vs placebo | RR 1.14 [0.98, 1.31] | 1 study · 969 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events within 6 months Casirivimab/imdevimab vs placebo | RR 0.82 [0.16, 4.21] | 1 study · 969 participants | Very low Downgraded: risk of bias, imprecision |
Bamlanivimab compared to placebo for postexposure prophylaxis of COVID‐19
Population: SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Infection with SARS‐CoV‐2 by day 30 Bamlanivimab vs placebo | RR 0.76 [0.59, 0.98] | 1 study · 966 participants | Moderate Downgraded: imprecision |
Development of clinical COVID‐19 symptoms within 30 days Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
All‐cause mortality by day 60 Bamlanivimab vs placebo | RR 0.83 [0.25, 2.7] | 1 study · 966 participants | Low Downgraded: imprecision |
Admission to hospital within 30 days Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Quality of life at longest Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 1 to 2 Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 3 to 4 Bamlanivimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: all grade by week 8 Bamlanivimab vs placebo | RR 1.12 [0.86, 1.46] | 1 study · 966 participants | Low Downgraded: imprecision |
Serious adverse events by week 8 Bamlanivimab vs placebo | RR 1.46 [0.73, 2.91] | 1 study · 966 participants | Low Downgraded: imprecision |
Casirivimab/imdevimab compared to placebo for postexposure prophylaxis of COVID‐19
Population: SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Infection with SARS‐CoV‐2 by day 30 Casirivimab/imdevimab vs placebo | RR 0.34 [0.23, 0.48] | 1 study · 1505 participants | High |
Development of clinical COVID‐19 symptoms within 30 days Casirivimab/imdevimab vs placebo | RR 0.19 [0.1, 0.35] | 1 study · 1505 participants | High |
All‐cause mortality by day 30 Casirivimab/imdevimab vs placebo | RR 3 [0.12, 73.43] | 1 study · 1505 participants | Low Downgraded: imprecision |
Admission to hospital by day 30 Casirivimab/imdevimab vs placebo | RR 0.11 [0.01, 2.06] | 1 study · 1505 participants | Low Downgraded: imprecision |
Quality of life at longest Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 1 to 2 Casirivimab/imdevimab vs placebo | no estimate extracted | NR | No studies |
Adverse events: grade 3 to 4 until data cut‐offb Casirivimab/imdevimab vs placebo | RR 0.5 [0.24, 1.02] | 1 study · 2617 participants | Low Downgraded: imprecision |
Adverse events: all grade until data cut‐offb Casirivimab/imdevimab vs placebo | RR 0.7 [0.61, 0.8] | 1 study · 2617 participants | High |
Serious adverse events until data cut‐offb Casirivimab/imdevimab vs placebo | RR 0.66 [0.3, 1.47] | 1 study · 2617 participants | Low Downgraded: imprecision |